Coeliac disease is relatively common with one in 100 people in the UK experiencing the condition and can be successfully treated with a gluten-free diet for life. Refractory coeliac disease affects 2 to 5% of these patients. They do not get better on a gluten-free diet and are more likely to develop a specific type of cancer with fatal consequences.
Professor David Sanders from Sheffield will lead the Network, working alongside Dr Jeremy Woodward at the collaborating centre in Cambridge. The RDCN will be looking to drive improvements in patient outcomes through greater understanding of refractory coeliac disease.
Professor David Sanders said: "The outlook for patients with refractory coeliac disease has been very poor, with 50% life expectancy post five years. The support from NHS England is wonderful as it will allow us an opportunity to collectively work on improving this awful situation for our patients."
RDCNs have been set up by the Government recently as part of its Strategy for Rare Diseases with a vision to lead to improved outcomes for patients with very rare diseases which have a prevalence of <1 in 10,000 of the population.
Earlier this year Coeliac UK, the largest independent charity for people who need to live gluten free, launched a research fund and accompanying fundraising appeal, aiming to raise £5 million to change the future for people with coeliac disease and gluten-related autoimmune conditions.
Sarah Sleet, Chief Executive of Coeliac UK, said: "This is the first time refractory coeliac disease will receive the focus from NHS England on new treatments and care that is so desperately needed. Now that we have this crucial recognition, we are working through our Research Fund to ensure we can make the investment and capitalise on this development and help improve the future for patients suffering with debilitating symptoms and we are delighted that Prof Sanders and Dr Woodward will be leading this collaborative network."
For further information: www.coeliac.org.uk/researchfund.